* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *
Full Coverage

Wyeth, Progenics drug misses goal in late-stage trial (AP)

yahoo.com
May 22, 2008
        
Story Timeline:  143 days

Thursday May 22, 7:48 am ET Wyeth, Progenics' Relistor misses goal in improving gastrointestinal function after surgery COLLEGEVILLE, Pa. (AP) -- Wyeth and Progenics Pharmaceuticals Inc. said Thursday that early results from a late-stage trial of their drug Relistor did not meet its goal in... [read full story]                    

Add Comment
Latest article on this story:

Wyeth and Progenics report preliminary results from clinical trials of Relistor

 pharmaceutical-business-review.com May 24, 2008
First article on this story:

Wyeth and Progenics: Relistor Phase 2 trial positive, Phase 3 trial failed? ? 3 mins ago

 pharmiweb.co.uk May 22, 2008
Selected publications with coverage of this story:
ibtimes.com orglex.com pharmaceutical-business-review.com yahoo.com drugpolicycentral.com tmcnet.com pharmiweb.co.uk finanznachrichten.de
RELATED
Found 13 documents:

Wyeth and Progenics report preliminary results from clinical trials of Relistor

pharmaceutical-business-review.com
May 24, 2008
        

Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals have reported preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of Relistor. The first of these studies, a Phase II trial, evaluated the effects of an oral...

Wyeth and Progenics report preliminary results from clinical trials of Relistor

orglex.com
May 24, 2008
        

Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals have reported preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of Relistor.[...] [ Pharmaceutical Business Review ] -...

                   

Progenics' Mixed Trial Data (at Motley Fool)

yahoo.com
May 23, 2008
        

By Brian Orelli May 23, 2008 Comments (0) Progenics Pharmaceuticals (Nasdaq: PGNX) and marketing partner Wyeth (NYSE: WYE) released both positive and negative clinical trial data on Thursday. Both of these were for their recently approved opioid-induced constipation (OIC) drug, Relistor. From the...

UPDATE - Wyeth, Progenics drug misses goal in Phase 3 study (at Reuters)

yahoo.com
May 23, 2008
        

NEW YORK, May 22 (Reuters) - Wyeth (WYE.N: ) and Progenics Pharmaceuticals Inc (PGNX.O: ) said on Thursday that an intravenous form of their Relistor drug failed to meet its main goal in a late-stage study for addressing gastrointestinal issues following surgery. The Phase 3 study, which also...

Health Winners & Losers: Progenics (at TheStreet.com)

yahoo.com
May 22, 2008
        

Health stocks generally rebounded Thursday, as the biotech sector slightly outpaced the broader markets. The Nasdaq and Amex biotechnology indices were up 1.3% and 1%, respectively, while the Amex pharmaceutical index added a less-robust gain of 0.2%. Partners Wyeth WYE...

                   

Progenics' Relistor Fails in POI, but Still Shows Future Promise

tmcnet.com
May 22, 2008
        

Progenics Pharmaceuticals Inc. and partner Wyeth Pharmaceuticals said a Phase III trial of bowel drug Relistor in patients with post-operative ileus (POI) did not meet any of the study's stated goals. But in a bright spot for Tarrytown, N.J.-based Progenics, a Phase II study of oral Relistor, did...

Progenics rises on oral Relistor mid-stage trial data

ibtimes.com
May 22, 2008
        

NEW YORK (AP) - Shares of Progenics Pharmaceuticals Inc. rose Thursday as positive midstage trial results for an oral version of its constipation drug Relistor offset the failure of the drug's intravenous version in another study. Progenics and partner Wyeth said the oral version effectively...

Progenics rises on oral Relistor mid-stage trial data (AP)

yahoo.com
May 22, 2008
        

Thursday May 22, 12:42 pm ET Progenics advances as trial data shows oral Relistor is effective again opioid constipation NEW YORK (AP) -- Shares of Progenics Pharmaceuticals Inc. rose Thursday as positive midstage trial results for an oral version of its constipation drug Relistor offset the...

Wyeth Pharmaceuticals, Progenics drug has study setback (at bizjournals.com)

yahoo.com
May 22, 2008
        

Wyeth Pharmaceuticals and Progenics Pharmaceuticals said Thursday their experimental drug Relistor, in intravenous form, did not meet primary or secondary end points related to treating bowel dysfunction caused by the use of opioid pain relief medication after abdominal...

Wyeth, Progenics drug misses goal in late-stage trial

ibtimes.com
May 22, 2008
        

COLLEGEVILLE, Pa. (AP) - Wyeth and Progenics Pharmaceuticals Inc. said Thursday that early results from a late-stage trial of their drug Relistor did not meet its goal in restoring gastrointestinal function following surgery to the intestine. The study, in a condition known as post-operative...

1 2 next